Back to Search
Start Over
Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition.
- Source :
-
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2009 Dec; Vol. 4 (12), pp. 1455-65. - Publication Year :
- 2009
-
Abstract
- Introduction: Loss of E-cadherin confers a poor prognosis in lung cancer patients and is associated with in vitro resistance to endothelial growth factor receptor inhibitors. Zinc finger E box-binding homeobox (ZEB)-1, the predominant transcriptional suppressor of E-cadherin in lung tumor lines, recruits histone deacetylases (HDACs) as co-repressors.<br />Methods: NSCLC cell lines were treated with HDAC inhibitors and analyzed for E-cadherin induction, growth inhibition and apoptosis. National Cancer Institute-H157 cells expressing ectopic E-cadherin were tested for tumorigenicity in murine xenografts.<br />Results: We found that treatment with MS-275, compared to vorinostat (SAHA), valproic acid or trichostatin A, was most effective in E-cadherin up-regulation and persistence in non-small cell lung cancers. As with other tumor types and HDAC inhibitors, MS-275 inhibited growth and induced apoptosis. Importantly, blocking E-cadherin induction by short hairpin RNA resulted in less inhibition by MS-275, implicating the epithelial to mesenchymal phenotype process as a contributing factor. In contrast to H460 and H661, H157 cells were resistant to E-cadherin up-regulation by HDAC inhibitors. However, E-cadherin was restored, in a synergistic manner, by combined knockdown of ZEB-1 and ZEB-2. In addition, H157 cells stably transfected with E-cadherin were markedly attenuated in their tumor forming ability. Lastly, combining MS-275 with the microtubule stabilizing agent, paclitaxel, or 17-(allylamino)-17-demethoxygeldanamycin, a heat shock protein 90 inhibitor, resulted in synergistic growth inhibition. Since MS-275 has no reported activity against HDAC6, which regulates both microtubule and heat shock protein 90 functions, other mechanisms of synergy are anticipated.<br />Conclusions: These results support the role of ZEB proteins and HDAC inhibitors in the pathogenesis and treatment of lung cancer.
- Subjects :
- Animals
Antineoplastic Agents pharmacology
Apoptosis drug effects
Benzamides pharmacology
Benzoquinones pharmacology
Blotting, Western
Cadherins antagonists & inhibitors
Cadherins genetics
Carcinoma, Non-Small-Cell Lung pathology
Carcinoma, Non-Small-Cell Lung prevention & control
Cell Proliferation drug effects
Female
Flow Cytometry
HSP90 Heat-Shock Proteins antagonists & inhibitors
Histone Deacetylase Inhibitors pharmacology
Histone Deacetylases chemistry
Histone Deacetylases metabolism
Homeodomain Proteins antagonists & inhibitors
Homeodomain Proteins genetics
Homeodomain Proteins metabolism
Humans
Hydroxamic Acids pharmacology
Lactams, Macrocyclic pharmacology
Lung Neoplasms pathology
Lung Neoplasms prevention & control
Pyridines pharmacology
RNA, Messenger genetics
RNA, Messenger metabolism
RNA, Small Interfering pharmacology
Rats
Rats, Nude
Repressor Proteins antagonists & inhibitors
Repressor Proteins genetics
Repressor Proteins metabolism
Reverse Transcriptase Polymerase Chain Reaction
Transcription Factors antagonists & inhibitors
Transcription Factors genetics
Transcription Factors metabolism
Tumor Cells, Cultured
Up-Regulation
Vorinostat
Zinc Finger E-box Binding Homeobox 2
Zinc Finger E-box-Binding Homeobox 1
Cadherins metabolism
Carcinoma, Non-Small-Cell Lung metabolism
Lung Neoplasms metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1556-1380
- Volume :
- 4
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 20009910
- Full Text :
- https://doi.org/10.1097/JTO.0b013e3181bc9419